ME LD1502

Expands required prostate cancer screening coverage beyond digital rectal exams and PSA tests to include medically necessary follow-up testing such as urinary analysis, serum biomarker testing, and MRI imaging

Replaces the current age-based eligibility requirement (men 50-72 years old, once annually) with coverage based on nationally recognized clinical practice guidelines supported by medical and scientific evidence

Prohibits insurers from imposing deductibles, copayments, coinsurance, or other cost-sharing for prostate cancer early detection services

Applies to individual and group health insurance policies, nonprofit hospital and medical service plans, and HMO contracts, excluding accidental injury, specified disease, hospital indemnity, Medicare supplement, and long-term care policies

Takes effect for policies issued or renewed on or after January 1, 2026, with an exception for high-deductible health plans used with health savings accounts pending IRS determination